As we began discussing authorship of a white paper summarizing our conclusions, we debated who our target audience should be and what kind of outcome we were hoping to achieve.

— Jennifer A. Doudna

Edits Medicine has an exclusive multimillion-dollar license with Juno Therapeutics to develop T cell therapies

— Jennifer A. Doudna

Have no doubt, this technology will — someday, somewhere — be used to change the genome of our own species in ways that are heritable, forever altering the genetic composition of humankind.

— Jennifer A. Doudna

In 2011, Rachel and I founded a company called Caribou Biosciences to commercialize the Ca's proteins.

— Jennifer A. Doudna

It’s not that I was categorically opposed to the idea of scientists and physicians using gene editing to introduce heritable changes into the human genome.

— Jennifer A. Doudna

PGD has also been used for other controversial purposes, such as the birth if so-called savior siblings, destined from the moment of implantation not only to live their own lives, but also to serve as organ or cell donors for a sibling.

— Jennifer A. Doudna

We founded Edits Medicine with $43 million in financing from three venture capital firms.

— Jennifer A. Doudna